H.C. Wainwright analyst Raghuram Selvaraju raised his price target for Acorda Therapeutics to $33 saying FDA approval for the company’s lead clinical candidate Inbrija bodes well for 2019. The label does not appear to contain any overly onerous restrictions, Selvaraju tells investors in a research note. He reiterates a Buy rating on Acorda.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.